Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

New therapeutic targets are revolutionizing colorectal cancer clinical management, opening new horizons in metastatic patients’ outcome. Polo Like Kinase1 (PLK1) inhibitors have high potential as antitumoral agents, however, the emergence of drug resistance is a major challenge for their use in clin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sonia Solanes-Casado, Arancha Cebrián, María Rodríguez-Remírez, Ignacio Mahíllo, Laura García-García, Anxo Río-Vilariño, Natalia Baños, Guillermo de Cárcer, Ana Monfort-Vengut, Víctor Castellano, Maria Jesús Fernández-Aceñero, Jesús García-Foncillas, Laura del Puerto-Nevado
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/7e7044e51a4443f1bd9c0e6e88deaf7a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!